Press Releases and Events
PRESS RELEASES
Press Release | September 11, 2023
Press Release | September 10, 2023
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
READ MORE
Press Release | September 9, 2023
Crinetics Announces September 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | August 10, 2023
Crinetics Announces August 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | August 8, 2023
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
READ MORE
Press Release | July 31, 2023
Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
READ MORE
Press Release | July 10, 2023
Crinetics Announces July 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | June 21, 2023
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
READ MORE
Press Release | June 12, 2023
Crinetics Announces June 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
SIGN UP
WEBCAST
PRESENTATIONTransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
